Metabolic osteoarthritis - relation of diabetes and cardiovascular disease with knee osteoarthritis
- PMID: 33253888
- PMCID: PMC8020447
- DOI: 10.1016/j.joca.2020.09.010
Metabolic osteoarthritis - relation of diabetes and cardiovascular disease with knee osteoarthritis
Abstract
Objective: There is an interest in identifying a metabolic OA phenotype. We therefore assessed the relation of diabetes and cardiovascular disease to prevalent and incident radiographic (ROA) and symptomatic knee osteoarthritis (SxOA).
Design: In two large cohort studies of individuals with or at risk for knee OA, the Multicenter Osteoarthritis Study (MOST) and Osteoarthritis Initiative (OAI), participants self-reported diabetes and cardiovascular disease (CVD) at baseline. We assessed the relation of baseline diabetes and CVD (exposures) to ROA and SxOA cross-sectionally and after 60 (MOST) or 48 (OAI) months of follow-up using logistic regression with GEE to account for 2 knees within an individual, adjusting for potential confounders.
Results: In MOST, 6,020 knees of 3,021 participants (60.1% female, mean ± SD age 62.5 ± 8.1, mean BMI 30.7 ± 6.0, 83.3% Caucasian) were included in the analyses. In OAI, 8,645 knees of 4,339 participants (58.2% female, mean ± SD age 61.1 ± 9.2, mean BMI 28.6 ± 4.8, 80.3% Caucasian) were included. We found no significant associations between prevalent diabetes or CVD and prevalent or incident ROA or SxOA. Effect estimates for prevalent ROA and SxOA ranged from 0.80 (95% CI 0.63-1.03) to 1.17 (0.91-1.51). Effect estimates for incident ROA ranged from 0.80 (0.58-1.11) to 0.88 (0.60-1.29) in MOST and from 0.75 (0.50-1.14) to 1.19 (0.81-1.74) in OAI, and for incident SxOA from 0.93 (0.65-1.31) to 1.22 (0.89-1.67) in MOST and from 0.82 (0.59-1.16) to 1.19 (0.85-1.66) in OAI).
Conclusions: Diabetes and CVD were not associated with prevalent or incident knee OA.
Keywords: Cardiovascular disease; Diabetes; Knee osteoarthritis; Metabolic.
Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.
Conflict of interest statement
Competing interest statement
Dr. Kuusalo has provided consulting services to Gilead, Pfizer, and Novartis, and reports lecture and travel fees from Abbvie, Lilly, Novartis, MSD, Orion, Pfizer, and Sanofi outside the submitted work. The other authors report no competing interests.
References
-
- Neumann J, Hofmann FC, Heilmeier U, Ashmeik W, Tang K, Gersing AS, et al. Type 2 diabetes patients have accelerated cartilage matrix degeneration compared to diabetes free controls: data from the Osteoarthritis Initiative. Osteoarthritis Cartilage 2018; 26: 751–61. DOI: 10.1016/j.joca.2018.03.010. - DOI - PMC - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical